er: 0001
ase list all Adverse Experiences
ease list all Adverse Experiences
ase list all Adverse Experiences
Serious
1= Yes
2=No
(If yes, complete
SAE form)
erious Initials

AE v1

Protocol Number: N	NIDA-CPU-0004	4		Site	Identific	ation Numbe	r: 980101	
GBR-12909 for Coca	aine Depender	тсе	Subject Identification Number:			r: 0001		
Study Day	UNSCHD					Date	e:	
			Form Not Done				(mm/d	ld/yyyy)
		ALCO	HOL BREATHALYZ	ZER TEST				
	1) Was alcoh	hol breathalyzer test p	erformed?		Yes	No 🔲	Jnknown	
	2) Date test	performed:				(m	m/dd/yyyy)	_
	3) Blood Alco	ohol content (BAC):				(mg	ŋ/ml)	_
	4) Provide co	omment for any actior	ı taken:					-
	Source C	Completed By (Initials)	:				ALB	REATH v1

Protocol Number: NIDA-CPU-0004 GBR-12909 for Cocaine Dependence			Site Identification Number: 980101					
			Subject Identification Number: 0001					
Study Day	UNSCHD	ŀ	Form Not Do	ne 🗌		Date: (mm/dd/yyyy)		
		ARC	CI SHORT F	ORM				
TI 40 II								
F (for false) for	ns may or may not describ or each item that does no	e how you feel right nov describe how you feel.	v. Mark I (for	true) next to each	n item that di	oes describe how you feel, and		
	Actual Time	(00:00	- 23:59)					
	·							
			71.					
			0	0	<u> </u>			
			0	0	<u> </u>			
			0	0				
			0	0				
			0	0				
			0	0				
			0	0	<u> </u>			
			0	0				
			0	0				
				0				
			0	0				
			0	0				
			10	0				
			10	0				
			0	0	<u> </u>			
				0	<u> </u>			
				0				
				0				
				0				
				0				
				0				
			-		Ī			
			0	0				
			0	0	<u> </u>			
			0	0				
			0	0				
				0				

27. Less discouraged	O True	○ False
	0	0
	0	0
	0	0
	0	0
	0	0
	0	0
	0	0
	0	0
	0	0
	0	0
	0	0
	0	0
	0	0
	0	0
	0	0
	0	0
	0	0
	0	0
	0	0
	0	0
	0	0
	0	0

C C	
Source Completed By (Initials):	

Protoc	ol Num	ber: NIC	PA-CPU-000	04]	Site Identi	ification Number:	980101
GBR-1	2909 fo	r Cocair	ne Depende	nce		Subject Identi	ification Number:	0001
Study	Day	1U	NSCHD		Form Not Done		Date:	
								(mm/dd/yyyy)
				BRIEF SU	BSTANCE CRAVING	G SCALE (BSCS)		
1)	The INT	ENSITY of	my craving, tl	nat is, how much I desired	d cocaine in the past 24 hrs	was:		
2)	The FRE	EQUENCY o	of my craving,	that is, how often I desire	ed cocaine in the past 24 hr	rs was:		
3)	The LEN	IGTH of tim	ne I spent in cr	raving for cocaine during t	he past 24 hrs was:			
4)	Write in	the NUMB	ER of times yo	u think you had craving fo	r cocaine during the past 24	1 hours:		
5)	Write in	the total T	IME spent crav	ving cocaine during the pas	st 24 hours:	HOURS	M	NUTES
6)	WORST	day: Durir	ng the past we	ek my most intense cravir	ng occurred on the following	g day:		
	7) T	he date fo	r that day was	:	(mm/dd/yyyy)		(If "All days the same, then si	kip to Question #8)
8)	The INT	ENSITY of	my craving, t	hat is, how much I desire	ed cocaine on that WORST	day was:		
9)	A 2nd cr	raved drug	during the pas	st 24 hours was:				
							Other	(specify)
10)	The INT	ENSITY of	my craving, th	nat is, how much I desired	I this second drug in the pa	st 24 hrs was:		
11)	The FRE	EQUENCY o	of my craving,	that is, how often I desire	ed this second drug in the p	ast 24 hrs was:		
12)	The LEN	IGTH of tim	ne I spent in cr	aving for this second drug	during the past 24 hrs was	:		
13)	A 3rd cr	aved drug	during the pas	t 24 hours was:				
							Other	(specify)
14)	The INT	ENSITY of	my craving, th	nat is, how much I desired	I this third drug in the past	24 hrs was:		
15)	The FRE	EQUENCY o	of my craving,	that is, how often I desire	ed this third drug in the pas	t 24 hrs was:		
16)	The LEN	IGTH of tim	ne I spent in cr	aving for this third drug d	uring the past 24 hrs was:			
				Source Comp	oleted By (Initials):			BSCS v1

Protocol Numl	ber: NIDA-CPU-0004	Site Identification Number: 980101	
GBR-12909 for	Cocaine Dependence	Subject Identification Number: 0001	
Study Day	UNSCHD	_	
	CONC	ICOMITANT MEDICATIONS	
Has the sul	bject taken any Concomitant Medications o	during this study? Yes No If yes, please list all below:	
Dose	Unit of Medication	Frequency Route of Administration	
Strength of Medication	CAP = capsule g = gram SPY = spray/squirt GR = grain GTT = drop ug = microgram UL = microliter mg = milligram mL = milliliter OZ = ounce PUF = puff SPY = spray/squirt SPY = suppository TSP = teaspoon TBS = tablespoon UNK = unknown OTH = other, specification OTH = other, specification TAB = tablet TAB = tablet UNK = unknown TAB = tablet TAB	BID = twice daily TID = three times a day OLD = four times a day OLD = every other day PRN = as needed INH = inhaled NAS = nasal IM = intramuscular IO = intraocular IV = intravenous UNK = unknown OTH = other, special VAG = vaginal	r
No. Medic	cation	Dose Unit Other Frequency Other	
Route		ate Stopped Cont.? Indication Initials m / dd / yyyy)	

CONMED v1

CHANGES IN SEXUAL FUNCTIONING QUESTIONNAIRE (CSFQ-Female) 1) Compared with the most enjoyable it has ever been, how enjoyable or pleasurable is your sexual life right now? 2) How frequently do you engage in sexual activity (sexual intercourse, masturbation, etc.) now? 3) How often do you desire to engage in sexual activity? 4) How frequently do you engage in sexual thoughts (thinking about sex, sexual fantasies) now? 5) Do you enjoy books, movies, music or artwork with sexual content? 6) How much pleasure or enjoyment do you get from thinking about and fantasizing about sex? 7) How often do become sexually aroused? 8) Are you easily aroused? 9) Do you have adequate vaginal lubrication during sexual activity? 10) How often do you become aroused and then lose interest? 11) How often do you experience an orgasm? 12) Are you able to have an orgasm when you want to?	01
CHANGES IN SEXUAL FUNCTIONING QUESTIONNAIRE (CSFQ-Female) 1) Compared with the most enjoyable it has ever been, how enjoyable or pleasurable is your sexual life right now? 2) How frequently do you engage in sexual activity (sexual intercourse, masturbation, etc.) now? 3) How often do you desire to engage in sexual activity? 4) How frequently do you engage in sexual thoughts (thinking about sex, sexual fantasies) now? 5) Do you enjoy books, movies, music or artwork with sexual content? 6) How much pleasure or enjoyment do you get from thinking about and fantasizing about sex? 7) How often do become sexually aroused? 9) Do you have adequate vaginal lubrication during sexual activity? 10) How often do you become aroused and then lose interest? 11) How often do you experience an orgasm? 12) Are you able to have an orgasm when you want to?	1
CHANGES IN SEXUAL FUNCTIONING QUESTIONNAIRE (CSFQ-Female) 1) Compared with the most enjoyable it has ever been, how enjoyable or pleasurable is your sexual life right now? 2) How frequently do you engage in sexual activity (sexual intercourse, masturbation, etc.) now? 3) How often do you desire to engage in sexual activity? 4) How frequently do you engage in sexual thoughts (thinking about sex, sexual fantasies) now? 5) Do you enjoy books, movies, music or artwork with sexual content? 6) How much pleasure or enjoyment do you get from thinking about and fantasizing about sex? 7) How often do become sexually aroused? 8) Are you easily aroused? 9) Do you have adequate vaginal lubrication during sexual activity? 10) How often do you become aroused and then lose interest? 11) How often do you experience an orgasm? 12) Are you able to have an orgasm when you want to?	
1) Compared with the most enjoyable it has ever been, how enjoyable or pleasurable is your sexual life right now? 2) How frequently do you engage in sexual activity (sexual intercourse, masturbation, etc.) now? 3) How often do you desire to engage in sexual activity? 4) How frequently do you engage in sexual thoughts (thinking about sex, sexual fantasies) now? 5) Do you enjoy books, movies, music or artwork with sexual content? 6) How much pleasure or enjoyment do you get from thinking about and fantasizing about sex? 7) How often do become sexually aroused? 8) Are you easily aroused? 9) Do you have adequate vaginal lubrication during sexual activity? 10) How often do you become aroused and then lose interest? 11) How often do you experience an orgasm? 12) Are you able to have an orgasm when you want to?	n/dd/yyyy)
2) How frequently do you engage in sexual activity (sexual intercourse, masturbation, etc.) now? 3) How often do you desire to engage in sexual activity? 4) How frequently do you engage in sexual thoughts (thinking about sex, sexual fantasies) now? 5) Do you enjoy books, movies, music or artwork with sexual content? 6) How much pleasure or enjoyment do you get from thinking about and fantasizing about sex? 7) How often do become sexually aroused? 8) Are you easily aroused? 9) Do you have adequate vaginal lubrication during sexual activity? 10) How often do you become aroused and then lose interest? 11) How often do you experience an orgasm? 12) Are you able to have an orgasm when you want to?	
3) How often do you desire to engage in sexual activity? 4) How frequently do you engage in sexual thoughts (thinking about sex, sexual fantasies) now? 5) Do you enjoy books, movies, music or artwork with sexual content? 6) How much pleasure or enjoyment do you get from thinking about and fantasizing about sex? 7) How often do become sexually aroused? 8) Are you easily aroused? 9) Do you have adequate vaginal lubrication during sexual activity? 10) How often do you become aroused and then lose interest? 11) How often do you experience an orgasm? 12) Are you able to have an orgasm when you want to?	
4) How frequently do you engage in sexual thoughts (thinking about sex, sexual fantasies) now? 5) Do you enjoy books, movies, music or artwork with sexual content? 6) How much pleasure or enjoyment do you get from thinking about and fantasizing about sex? 7) How often do become sexually aroused? 8) Are you easily aroused? 9) Do you have adequate vaginal lubrication during sexual activity? 10) How often do you become aroused and then lose interest? 11) How often do you experience an orgasm? 12) Are you able to have an orgasm when you want to?	
5) Do you enjoy books, movies, music or artwork with sexual content? 6) How much pleasure or enjoyment do you get from thinking about and fantasizing about sex? 7) How often do become sexually aroused? 8) Are you easily aroused? 9) Do you have adequate vaginal lubrication during sexual activity? 10) How often do you become aroused and then lose interest? 11) How often do you experience an orgasm? 12) Are you able to have an orgasm when you want to?	
6) How much pleasure or enjoyment do you get from thinking about and fantasizing about sex? 7) How often do become sexually aroused? 8) Are you easily aroused? 9) Do you have adequate vaginal lubrication during sexual activity? 10) How often do you become aroused and then lose interest? 11) How often do you experience an orgasm? 12) Are you able to have an orgasm when you want to?	
7) How often do become sexually aroused? 8) Are you easily aroused? 9) Do you have adequate vaginal lubrication during sexual activity? 10) How often do you become aroused and then lose interest? 11) How often do you experience an orgasm? 12) Are you able to have an orgasm when you want to?	
8) Are you easily aroused? 9) Do you have adequate vaginal lubrication during sexual activity? 10) How often do you become aroused and then lose interest? 11) How often do you experience an orgasm? 12) Are you able to have an orgasm when you want to?	
9) Do you have adequate vaginal lubrication during sexual activity? 10) How often do you become aroused and then lose interest? 11) How often do you experience an orgasm? 12) Are you able to have an orgasm when you want to?	
10) How often do you become aroused and then lose interest? 11) How often do you experience an orgasm? 12) Are you able to have an orgasm when you want to?	
11) How often do you experience an orgasm? 12) Are you able to have an orgasm when you want to?	
12) Are you able to have an orgasm when you want to?	
13) How much pleasure or enjoyment do you get from your orgasms?	
14) How often do you have painful orgasm?	
Source Completed By (Initials): TOTAL SCORE:	_
CSF	QFEML v1

Proto	col Nui	mber: NIDA-CPU-0004		Site Identification Number:	980101			
GBR-	12909 f	or Cocaine Dependence		Subject Identification Number				
Study	Day	UNSCHD	Form Not Done	Date:				
					(mm/dd/yyyy)			
		CHANGES	IN SEXUAL FUNCTIONING QUI	ESTIONNAIRE (CSFQ-Male)				
1)	Compare	ed with the most enjoyable it has e	ever been, how enjoyable or pleasurable is y	your sexual life right now?				
2)	How free	quently do you engage in sexual ac	ctivity (sexual intercourse, masturbation, etc	.) now?				
3)	How ofte	en do you desire to engage in sexu	ual activity?	ļ				
4)	How free	quently do you engage in sexual th	oughts (thinking about sex, sexual fantasies) now?				
5)	Do you e	enjoy books, movies, music or artv	ork with sexual content?	J				
6)	How mud	ch pleasure or enjoyment do you g	et from thinking about and fantasizing abou	t sex?				
7)	How ofte	en do you have an erection related	or unrelated to sexual activity?					
8)	Do you g	get an erection easily?						
9)	Are you	able to maintain an erection?						
10)	How ofte	en do you experience painful prolor	ged erections?					
11)	How ofte	en do you have an ejaculation?						
12)	Are you	able to ejaculate when you want	:0?					
13)	How mu	ch pleasure or enjoyment do you ç	get from your orgasms?					
14)	How ofte	en do you have painful orgasm?						
		Source C	ompleted By (Initials):	TOTAL SCORE:				
					CSFQMALE v1			
					OSFQWALE VI			

Protocol Nu	mber: NIDA-CP	U-0004]	Site Identification Nur	mber: 980101
GBR-12909 1	for Cocaine Dep	endence		mber: 0001	
Study Day	UNSCHD		_		<u> </u>
			DEATH REPORT		
	9	Subject Date of Death		(mm/dd/yyyy)	
	- \	Was autopsy performed?	Yes	No Unknown	
		If yes, is autopsy report av	vailable?	□ No	
	-	Is cause of death known?	Yes	No	
	If yes, in the inves	stigator's clinical judgement, wha	at was the primary cause of death	?	
	Narrative descripti	ion of death (include information	about why cause of death is unkn	nown, if applicable.)	
		Source	Completed By (Initials):		
			, , , , ,		DEATH v1

Protocol Number: NIDA-CPU-0004	Site Identification Number: 980101
GBR-12909 for Cocaine Dependence	Subject Identification Number: 0001
Study Day UNSCHD	Form Not Done (mm/dd/yyyy)
	DEMOGRAPHICS
DEMOGRAPHIC DATA	
1) Gender Male	Female
2) Date of Birth	(mm/dd/yyyy)
Indicate which single major	
□ White and of Himania Onic	
White, not of Hispanic Orig	in American Indian or Alaska native Other, (specify):
African American, Black, n	
Asian or Pacific Islander	Unknown
4) Ethnicity/Race all that app	oly:
For each of the following, answ	ver Yes to all that apply and No to those that do not.
Yes No White	
	African American, or Negro
	can Indian or Alaskan Native
	h, Hispanic, or Latino (mark all that apply) can-American, or Chicano
Puerto Rican	Other (specify)
	(mark all that apply)
Asian Indian	Korean
Chinese	Vietnamese
Filipino	Other (specify)
Japanese	
	Hawaiian or Pacific Islander (mark all that apply)
Native Hawaii	
Guamanian or	
	(specify)
Participant chooses	<u>not to answer</u>
EMPLOYMENT/SUPPORT STATUS	
	(months)
1) Education completed (GED	
2) <u>Usual employment pattern</u>	
1 - Full time (35+ hours/w	
2 - Part time (regular hours	
3 - Part time (irregular hou 4 - Student	urs, day work) 8 - Unemployed 9 - In controlled environment
4 - Student 5 - Military Service	

3)	Usual employment patter	n, past 3 years:						
	1 - Full time (35+ hours/w	veek)	6	- Retired/Disa	bled			
	2 - Part time (regular hours	s)		- Homemake	r			
	3 - Part time (irregular hou		8	- Unemploye	d			
	4 - Student		9	- In controlled	d environment			
	5 - Military Service							
4)	Marital Status:							
	1 - Legally married		□ 4 ·	- Separated				
	2 - Living with partner/coh	abitating		- Divorced				
	3 - Widowed		_	- Never Marri	ed			
UG/A	LCOHOL USE							
		Days in Past	Lifetime		ROUT	E OF ADMINI	STRATION	
		30 Days	Years	oral	nasal	smoking	injection	N/A
ccord	ing to the interviewer, whic	h substance is the	major problem	n? (Salact	only one ito	m)		
ocoi u	0 - No problem		- Opiates/analges		only one ite	12 - Hallucinoge	ens	
	1 - Alcohol (any)		- Barbiturates			13 - Inhalants		
	2 - Alcohol to intoxication		- Sed./hyp./tranq.	/benzos.		14 - Nicotine		
	3 - Heroin		- Cocaine				d Drug addictiion	
	4 - Methadone/LAAM (pre	_	0- Amph./metham	ph.		16 - Polydrug a		
	5 - Methadone/LAAM (illici		1 - Cannabis			, g =		
	<u> </u>	<u></u>						
	Source	Completed By (Ini	tials):				DEMOG	v 1

Protocol Number: NIDA-CPU-0004	Site Identific	ation Number: 980101
GBR-12909 for Cocaine Dependence	Subject Identification	ation Number: 0001
Study Day UNSCHD	Form Not Done	Date: (mm/dd/yyyy)
12-Lead ELECTR	OCARDIOGRAM	Normal Intervals
		QRS: 60 - 100 msec
		If Abnormal,
Hour Test Time Heart Rate PI	R QT QRS R-R QTc	E C G Clinically
ECG Type (00:00-23:59) Beats/minute (mse	ec) (msec) (msec) (msec) (msec)	Abnormal? Significant?
12-Lead		Yes No Yes No
Specify Abnormality as recorded on ECG tracing		·
Source Completed By (Initials):		ECG1 v1

Protocol Number: NIDA-CPU-0004 GBR-12909 for Cocaine Dependence					Site Identification Number: Subject Identification Number:							
Study Day UNSCHD					Form	Not Done			Date:		ld/yyyy)	
			12 LEA	D ECG a	and DIGIT	TAL ACQU	JISITION	N ECG				
Hour	Test Type	Time (00:00-23:59)	Heart Rate Beats/minute	PR (msec)	Q T (msec)	QRS (msec)	R-R (msec)	QTc (msec)	ECG Abnormal?	C	Abnormal, clinically gnificant?	_
		Source Co	mpleted By (Initi	als):							ECGD	IGIT v1

Protocol Number: NIDA-CPU-0004								Identification Numb	
GBR-12909 f	Forn				Form Not Done (mr				
Hour	Test Type	Time (00:00-23:59)	PR (msec)	QT (msec)	QRS (msec)	R-R (msec)	QTc (msec)	ECG Abnormal?	If Abnormal, Clinically Significant?
		Source Complete	d By (Initia	ls):					ECGPRFL1 v ²

Protocol Number:	otocol Number: NIDA-CPU-0004					980101				
GBR-12909 for Co	caine Depe	endence				Subj	ect Ident	ification Number	0001	
Study Day UNSCHD				Form Not Done			(mm/dd/yyy	y)		
		12 LE	AD ECG	and DIG	SITAL AC	QUISITI	ON ECG	(DAYS 12 - 18)		
Hour since last dose/Day	Test Type	Time (00:00-23:59)	PR (msec)	QT (msec)	QRS (msec)	R-R (msec)	QTc (msec)	ECG Abnormal?	If Abnormal, Clinically Significant?	
										_
	I	'	l							_
	S	ource Completed	By (Initials	s):						
									ECGPRF	L2 v1

rotocol Number: NIDA-CPU-000	04	Site Identification Number: 980101								
BR-12909 for Cocaine Depende	ence	Subject Identification Number: 0001								
tudy Day UNSCHD]									
	END O	F TRIAL								
1) Data of last violt?	(mm/dd/yyy	an)								
1) Date of last visit?										
2) Was the subject terminate	d early from the trial?	Yes No								
Reason subject's participa	ntion has ended (Mark all that a	apply):								
Subject completed stud	dy without a re-challenge phase.									
Subject completed stud	dy with a re-challenge phase.									
Subject was determined	d after enrollment to be ineligible. (P	rovide comments)								
Subject requested to w	ithdraw. (Provide comments)									
	Subject experienced an intercurrent illness, unrelated medical condition, or clinically significant adverse events which prompted early termination. (Complete AE form, provide comments)									
Subject terminated for in this category. Provide	administrative reasons. (Include pro e comments)	otocol non-compliance								
Subject transferred to a	another treatment program (check	all that apply)								
Methadone	Drug Free	☐ Inpatient Detox or Treatment								
LAAM	Therapeutic Community	y Other (specify)								
Subject was incarcerate	ed.									
Subject became pregna	ant.									
Subject developed sens	sitivity to study agent.									
Subject was lost to follo	ow-up.									
Subject moved from are										
Subject died. (If subject	t died, a Death Report Case Report	Form must be completed)								
Subject can no longer a										
Subject no longer atten	ds clinic.									
Subject is in a controlle										
Subject is a screen failu										
Other (Provide commer	its)									

ENDTRIAL v1

Protocol Number: NIDA-CPU-0004 GBR-12909 for Cocaine Dependence			Site Identi Subject Identi	ification Nu ification Nu		980101
Study Day	UNSCHD					
			ENROLLMENT]		
	Is subject eligible for par	ticipation based	on the Eligibility Criteria?	Yes	No No	
	If yes, was su	oject enrolled int	o the study?	Yes	No	-
	If subject was	enrolled in the s	tudy, date enrolled:	(mm/	dd/yyyy)	Ī
	If not enrolled, indicate	reason	failed to return to clinic			-
			declined study participation			
			other, specify:			
	Source Comp	leted By (Initials)	:		[ENROLL v1

Protocol Number: NIDA-CPU-0004	Site Identification Numb	er: 980101
GBR-12909 for Cocaine Dependence	Subject Identification Numb	er: 0001
Study Day UNSCHD	Da	(mm/dd/yyyy)
	EXCLUSION CRITERIA	
Participant must not:		
According to DSM-IV criteria as determined by struct have any current diagnosis or history of major psychi disorders secondary to drug use or be mentally or leg	atric illness other than drug dependence or	Yes No
According to DSM-IV criteria be dependent upon or a and alcohol or have physiological dependence upon a		Yes No
Note: The subjects that are not physically dependent	etamines, barbiturates, benzodiazepines, methadone,	Yes No
Use any prescription drugs within 14 days of enrollmed or if female, have used an oral contraceptive, Depo-F contraceptive system within 30 days of enrollment.	ent or non-prescription drugs within 7 days of enrollment, Provera, Norplant or intrauterine progesterone	Yes No
5. Be pregnant or lactating.		Yes No
Have a history of liver disease or of any elevation of alanine aminotransferase (ALT) exceeding the upper liver.		Yes No
Have donated a unit of blood or participated in any centrolling on the study.	other clinical investigation within 4 weeks of	Yes No
Have a history of any illness, a family history of early that in the opinion of the investigator might confound administering the investigational agents to the subjection.		Yes No
9. Be seropositive for hepatitis B surface antigen, hepatypes 1.	titis C antibody, or human immunodeficiency virus (HIV)	Yes No
10. Have a diagnosis of adult (i.e., 21 years or older) ast including those with a history of acute asthma within (past 2 years) treatment with inhaled or oral beta-ago	the past two years, and those with current or recent	Yes No
11. Have a mean baseline absolute neutrophil count (from mean total white blood cell count of less that 2 x 10	m Days -2, -1, and 0) of less than 1000 cells/mcL and a cells/mcL.	Yes No
Note: All answe	ers to EXCLUSION CRITERIA must be NO.	
Source Completed By (Initials)	:	EXCLUS v1

Protoc	ol Number	r: NIDA-CPU-0	004		Site Ider	ntification Number:	980101
GBR-1	2909 for C	ocaine Depend	lence		Subject Ider	ntification Number:	0001
Study	Day	UNSCHD		Form Not I	Done	Date:	(mm/dd/yyyy)
				FOLLOW-UP)		
1)		oct been made w		dd/yyyy)	es ONo		
2)		o, date:	s contact been made with sor	3333.	s/her status?	O Yes O	No
	If yes, has	the subject died?	O Yes O No	(If the subject died, a Dea	ath Report CRF must be comp	leted)	
3)	If contact h	as not been made	with the subject, explain:				
4)	Does subject	ct report use of an	y of the following and if so, f	or how many days in th	e last week?	(Check all that apply).	
		DRUG	<u>Days Used</u>	<u>DRUG</u>	<u>Days Use</u>	e <u>d</u>	
		Cocaine Methamphetamin Amphetamines Benzodiazepines Alcohol	ne	Sedatives Nicotine Opiates Barbiturate None	es E		
		Marijuana		Other		(specify)	
5)	Does the su	ubject report curren	tly receiving treatment for dr	ug or alcohol abuse/depe	endence?	O Yes O	No
6)	Does the su abuse treati		e/she would take the study d	lrug again if it were gene	erally available for subst	ance Yes O	No O Unknown
7)	Have any a	dverse events occ	urred?	○ Yes ○ No	Ī		
8)	Have any se	erious adverse eve	nts occurred?	O Yes O No	(If yes, a Serious Adverse E	event CRF must be completed)	
9)	Additional c	comments:					
		Source Co	mpleted By (Initials):				FOLLOWUP v1

BR-12909 for Cocaine Deper	ndence		Subject Identification Number:						
udy Day UNSCHD			Form Not [Done 🗌		Date	(mm/dd/yyyy		
			HEMATO	LOGY					
<u>Complete</u> <u>Blood Count</u>	Std. Quantity	Standard Unit	Other Unit	<u>Normal</u>	Abnormal	Abnormal Significant	<u>Not</u> <u>Done</u>		
Hemoglobin									

Protocol Number: NIDA-CPU-0004	Site Identification Number: 980101					
GBR-12909 for Cocaine Dependence	Subject Identification Number: 0001					
itudy Day UNSCHD	Date:					
	(mm/dd/yyyy)					
INC	ELUSION CRITERIA					
Participant must:						
Be African American between 18 and 45 years-of-age.	Yes No					
2. Be within 20% of ideal body weight and must weigh at least 45 k	J. Yes No					
3. Understand the study procedures and provide written informed co	sent. Yes No					
4. Be volunteers who are dependent on or abusing cocaine according to DSM-IV criteria and are non-treatment seeking at time of study.						
Currently use cocaine as determined by self report and positive use within 30 days of the start of the study.	ne test for BE					
6. Be female and have a negative pregnancy test within 72 hours printed investigational agent and agree to use one of the following method postmenopausal, have had hysterectomy or have been sterilized, a. complete abstinence from sexual intercouse b. diaphragm and condom by partner c. intrauterine device and condom by partner d. sponge and condom by partner Note: oral contraceptives, Depo-Provera, Norplant and intrauterine system are not allowed.	s of birth control, or be or be male.					
7. Be judged by the examining physician or his/her designee after a to be in good health, without clinically significant abnormalities.	istory and physical examination					
Have an ECG performed that demonstrates normal sinus rhythm a	nd no clinically significant arrhythmias.					
Note: All answers to INC	LUSION CRITERIA must be YES.					
Source Complete	d By (Initials):					

Protocol Nui	mber: NIDA-CPU-0004		Si	te Identification Number: 980	101					
GBR-12909 f	or Cocaine Dependence		Subje	ct Identification Number: 00	01					
Study Day	UNSCHD		_	Date:						
			Form Not Done	(mı	m/dd/yyyy)					
					_					
		I	NFECTIOUS DISEASE ASSES	SSMENT						
	Indicate whether the laboratory value is NEGATIVE: negative test result, POSITIVE: but DOES NOT EXCLUDE subject from participation or continued study participation, POSITIVE SIGNIFICANT: significant during screening means subject is ineligible for study; significant while on study means consider reporting result as adverse event if unexpected and at least possibly related to investigational agent or early termination of the subject from study, INDETERMINANT: result was not interpretable.									
	Infectious Disease		<u>Result</u>	Provide comments for any about	normal_					
<u>Hepati</u>	tis B surface antigen result	ſ								
<u>Hepati</u>	tis B surface antibody result	Ţ								
<u>Hepati</u>	tis B core antibody result	[
<u>Hepati</u>	tis C virus antibody result	[
HIV ty	<u>pe 1</u>	Ī								
HIV typ	<u>pe 2</u>	[
	Source Completed	By (Initials):		Т	NFECDIS v1					

Protocol Nu	mber: NIDA-CPU-000)4]	ation Number:	980101				
GBR-12909 1	for Cocaine Depende	nce		ation Number:	0001				
Study Day	UNSCHD		Form Not Do	ne 🗌					
INVESTIGATIONAL AGENT ADMINISTRATION									
Line No.	Day of Week	Date	No. of Tablets Administered	Time Administered	Administered By				
	Source Completed By (Initials):								

rotocol Number: NIDA-CPU-0004 BR-12909 for Cocaine Dependence			Sul	Site Identification			
	UNSCHD		Form Not Done				
		LAB	3 TRACKING				
Date: (mm/dd/yyyy)	Tests:	Barcode / Tracking #	Barcode / Tracking # For Lab Corp	Actual Time (00:00-23:59)	Completed By (Initials)		
	Plasma Alcohol GBR 12909 Assay						
	Urine Specimen Hematology						
	Chemistry Urinalysis						
Comments	<u>s:</u>						
					L	ABTRACK v	

ior Cocaine Dependence UNSCHD	Form Not C		Site Identification Nibject Identification N		уууу)
LAB TRACKI	NG PK FOR	GBR 12909	(DAY 11-18)		
Time of Dosing		GBR Assay	Actual Time (00:00-23:59)		
Prior to GBR 12909 Administration/ Day	11				
				[
				[_	
				<u></u>	
				-	
				-	
				-	
				<u> </u>	
				<u></u>	
				<u>-</u>	
				<u>-</u>	
				<u>-</u>	
				-	
				_	
1					
				<u> </u>	
				<u></u>	
[[
Source Completed By (Initials):	Γ				
				LABT	RK2 v1

Pro	tocol Number: NIDA-CPU-0004				Site	e Identification Number: 980101
GBR-12909 for Cocaine Dependence					Subject	Identification Number: 0001
Stu	dy Day UNSCHD		_	N	- 🗖	Date: (mm/dd/yyyy)
				orm Not Don		(11111/44/7999)
			MEDI	CAL HISTOR	Y	
	Disorder	<u>Yes</u> excludes	<u>Yes</u> doesn't exclude	<u>No</u> <u>history of</u> <u>disorder</u>	<u>Not</u> evaluated	If yes, specify or describe
	Allergies: drug					in yes, specify of describe
_	Allergies: other, specify					
۷.	Allergies, other, specify					
	Sensitivity to Agents/Compounds					
_	History of Asthma					
_	HEENT					
_	Cardiovascular					
	Renal					
_						
_	Hepatic					
_	Pulmonary					
	Gastrointestinal					
_	Musculoskeletal					
_	Neurologic					
	Psychiatric					
_	Dermatologic					
_	Metabolic					
_	Hematologic					
_	Endocrine					
	Genitourinary					
	Reproductive System					
20.	Seizure					
21.	Infectious Disease					
22.	Other 1, specify:					
23.	Other 2, specify:					

24. Was major surgery ever performed?	Yes	No (If Yes, Ii	st surgeries:)				
Type of Surgery		Date of Surgery (mm/dd/yyyy)	<u>Yes</u> excludes	<u>Yes</u> doesn't exclude	<u>No</u>		
25. test							
26.							
27.							
28.							
29.							
30.							
31.							
TOBACCO HISTORY							
32. Has subject used any tobacco product (e.g. cigarettes, cigars, pipe, chewing tobacco) in the past week? 33. Has subject ever used any tobacco product for at least one year? 34. If yes, number of years tobacco used?							
Source Completed By (Initials):				MEC	DHIST v1		

Protocol Number: NIDA-CPU-0004	Site Identification Num	nber: 980101
GBR-12909 for Cocaine Dependence	Subject Identification Num	nber: 0001
Study Day UNSCHD	Form Not Done	Date: (mm/dd/yyyy)
	McLEAN HOSPITAL	
OVERT AGO	GRESSION SYMPTOM CHECK LIST	
Indicate with an appropriate check mark whether or not	you have engaged in any of the following behaviors durin	ng -
the past day.	the past week.	
the past month.	the past year.	
any time in your life).	
<u>'</u>	. VERBAL AGGRESSION	
I have made loud noises, or shouted angrily		Yes No
2. I have yelled mild personal insults (e.g., "You're stupid")		Yes No
I have cursed viciously, or used foul language in anger		Yes No
I have made clear threats of violence to myself or others		
	CAL ACCDESSION TOWARD SELF	Yes No
I have picked or scratched at my skin, hit myself, pulled my h	CAL AGGRESSION TOWARD SELF air. or hurt myself without causing	
any actual injury.		Yes No
2. I have banged my head, hit my fist into objects, thrown myst	elf down, or hurt myself in such a way	
as to inflict minor injury		Yes No
 I have made small cuts, bruises, or burns on my body, or have visibly damage my skin 	ve hurt myself in such a way as to	Yes No
I have cut myself deeply, bit myself till I bled, inflicted internation a potentially serious way	al injury, broke bones, or hurt myself	Yes No
III. PHYSICA	AL AGGRESSION TOWARD OBJECTS	
I have slammed doors, scattered my clothes, or made a mess	out of anger	Yes No
2. I have thrown objects down, kicked furniture without breaking	g it, or have marked walls	Yes No
3. I have broken objects or smashed windows		Yes No
4. I have set a destructive fire, or damaged valuable property		Yes No
IV. PHYSICA	AL AGGRESSION TOWARD OTHERS	
 I have made threatening gestures, swung at someone, or grab of anger 	bbed at someone's clothing out	Yes No
2. I have hit, kicked pushed someone or pulled their hair, withou	t injuring them	Yes No
I have attacked someone, causing mild-to-moderate physical in or threatened someone with a dangerous weapon	njury (bruises, sprains, welts),	Yes No
 I have attacked someone, causing severe physical injury (e.g. internal injury) 	, broken bones, deep cuts,	Yes No
	V. SUICIDALITY	
I have daydreamed or fantasized about committing suicide		Yes No
2. I have formulated a detailed suicide plan, but did not make an	attempt	Yes No
3. I have taken an overdose of medications, mixed alcohol and pi	ills, or engaged in other hazardous	
behavior to escape from my feelings, with little concern for m absolutely certain intent to die		Yes No
 I have taken a massive overdose, tried to hang myself, or dir attempt with an absolutely certain intent to die 	ectly made a nearly lethal suicide	Yes No
Source Completed By (Initials):		MOASCL v1

Protocol Number: NIDA-CPU-0				Site Identification Number:	980101	
GBR-12909 for Cocaine Depend			s	ubject Identification Number:	0001	
Study Day UNSCHD				Date:		
		F	orm Not Done			(mm/dd/yyyy)
		ABBREVIA	TED PHYSIC	AL EXAM	IINATION	
General Exam	<u>Normal</u>	<u>Abnormal</u>	Abnormal Significant	<u>Not</u> Done	If Abnormal, explain below	
Cardiovascular						
Lungs						
Neuropsychiatric mental status						
Neuropsychiatric sensory/motor						
Skin						
Source Cor	mpleted By (Ir	itials):			РН	YEXAM2 v1

Protocol Number: NIDA-CPU-0004					Site Identification Number: 980101
GBR-12909 for Cocaine Depende	ence			:	Subject Identification Number: 0001
Study Day UNSCHD					Date:
		F	orm Not Done		(mm/dd/yyyy)
		PHYS	SICAL EXAMI	NATIO	V
_					
Height:		inches centimeters	Wei	ght:	pounds
	L				
General Exam	<u>Normal</u>	<u>Abnormal</u>	<u>Abnormal</u> Significant	<u>Not</u> <u>Done</u>	If Abnormal, explain below
Oral (mouth)					
Head and Neck					
EENT					
Cardiovascular					
Chest					
Lungs					
Abdomen (include liver/spleen)					
Extremities					
Skin, Hair, Nails					
Neuropsychiatric mental status					
Neuropsychiatric sensory/motor					
Musculoskeletal					
General Appearance					
Rectal					
Prostate					
Breast					
Lymph					
Genital					
Pelvic					
Other (specify)					
Other (specify)					
Source Comp	leted By (Init	ials):			PHYSEXAM v1

col Number: NIDA-CPU-0004	Site Identification Number: 980101
12909 for Cocaine Dependence	Subject Identification Number: 0001
y Day UNSCHD	Form Not Done (mm/dd/yyyy
	PREGNANCY
Was a pregnancy test performed (If no, skip to birth control method)	Yes No IF Yes, type: Urine Serum
Pregnancy test result:	O Positive Negative Unknown Not applicable, subject is male
Pregnancy test comments:	
Is the subject lactating?	Yes No Not Applicable
Is the subject using an acceptable birth control?	le method of O Yes O No
What method of birth control is the	he subject using?
Barrier (diaphragm or condom) wit Intrauterine progesterone contract Lovenorgestrel implant (Norplant) Medroxyprogesterone acetate cont	ceptive system (IUD)

Protocol Num	ber: NIDA-CPU-0004		Site Identification Numbe	er: 980101
GBR-12909 for	r Cocaine Dependence	S	Subject Identification Numbe	er: 0001
Study Day	UNSCHD			
	PRIC	OR MEDICATIONS		
Has the sub	oject taken any medications in the PAST 30 Da	AYS?	Yes No If yes, please list all	below:
Dose	Unit of Medication	Frequency	Route of Administ	tration
Strength of Medication	CAP = capsule g = gram GR = grain GTT = drop ug = microgram uL = microliter mg = milligram mL = milliliter OZ = ounce PUF = puff SPY = spray/squirt SUP = suppository TSP = teaspoon TBS = tablespoon UNK = unknown OTH = other, specify	ONCE = single dose QD = once daily BID = twice daily TID = three times a day QID = four times a day QOD = every other day PRN = as needed OTH = other, specify	PO = oral AUR TD = transdermal IA INH = inhaled NAS IM = intramuscular IV = intravenous UNK REC = rectal OTH VAG = vaginal SQ = subcutaneous SL = sublingual	= auricular = intra-articular = nasal = intraocular = unknown = other, specify
No. Med	lication	Dose Unit	Other Frequency (specify)	Other (specify)
Route		Stopped Cont.? Indication	n	Initials

PRIORMED v1

otocol Number: NIDA-CP	J-0004			Site I	dentification	Number:	980101
GBR-12909 for Cocaine Dependence Study Day UNSCHD				Subject I	dentification	Number:	0001
						Ī	
		SER	IOUS ADVERSE	EVENT			
DEMOGRAPHIC INFORMAT	ION						
Enrollment Date		(mm/dd/yyyy)	<u>Gende</u>	<u>r</u> Male	Female		
Date of Birth		(mm/dd/yyyy)					
Race							
White, not of Hispanic Or	igin	Am	nerican Indian or Alask	a Native			
Hispanic or Latino		Ot	her, (specify):				
African American, Black,	not of Hispanio	c Origin					
Asian or Pacific Islander		Un	known				
<u>Height</u>	inches	centimeters	Weight	<u>t</u>	pounds	kilograi	ms
AE/Diagnosis:				-			
7127 Biugilosisi							
ERIOUS ADVERSE EVENT SAE Description							
		(mm/dd/yyyy)					
		(mm/dd/yyyy)	Initial Date repo	orted to FDA:			(mm/dd/yyyy)
SAE Description Onset Date	by:	(mm/dd/yyyy)	Initial Date repo				(mm/dd/yyyy)
SAE Description Onset Date Reported to FDA by:	· .	(mm/dd/yyyy)	-	o sponsor:			
Onset Date Reported to FDA by:	· .	(mm/dd/yyyy) moderate	Date reported to	o sponsor:			 (mm/dd/yyyy)
Onset Date Reported to FDA by: Reported to NIDA by	i mild	moderate	Date reported to	o sponsor:			 (mm/dd/yyyy)
Onset Date Reported to FDA by: Reported to Sponsor Reported to NIDA by Severity grade	i mild	moderate nal agent?	Date reported to	o sponsor: orted to NIDA:	unknown		 (mm/dd/yyyy)
Onset Date Reported to FDA by: Reported to Sponsor Reported to NIDA by Severity grade Was SAE related to in	mild nvestigation probab	moderate nal agent? ly possibly	Date reported to	o sponsor: orted to NIDA:			 (mm/dd/yyyy)
Onset Date Reported to FDA by: Reported to Sponsor Reported to NIDA by Severity grade Was SAE related to in	mild nvestigation probab	moderate nal agent? ly possibly	Date reported to	o sponsor: orted to NIDA: finitely not			 (mm/dd/yyyy)
SAE Description Onset Date Reported to FDA by: Reported to Sponsor Reported to NIDA by Severity grade Was SAE related to in definitely Action taken regarding	mild nvestigation probab ng investig	moderate nal agent? ly possibly ational agent	Date reported to	orted to NIDA: finitely not Other action none			 (mm/dd/yyyy)
SAE Description Onset Date Reported to FDA by: Reported to Sponsor Reported to NIDA by Severity grade Was SAE related to in definitely Action taken regarding	mild nvestigation probab probab ng investig	moderate nal agent? ly possibly ational agent reduced dose	Date reported to	finitely not Other action none remedial the	(s) taken	ogic	 (mm/dd/yyyy)
SAE Description Onset Date Reported to FDA by: Reported to Sponsor Reported to NIDA by Severity grade Was SAE related to in definitely Action taken regarding none discontinued pe	mild nvestigation probab probab ng investig	moderate nal agent? ly possibly ational agent reduced dose increased dose	Date reported to	finitely not Other action none remedial the	(s) taken erapy - pharmacol	ogic	 (mm/dd/yyyy)
SAE Description Onset Date Reported to FDA by: Reported to Sponsor Reported to NIDA by Severity grade Was SAE related to in definitely Action taken regarding none discontinued permitted discontinued termitted	mild probab probab ng investig rmanently mporarily	moderate nal agent? ly possibly ational agent reduced dose increased dose	Date reported to	finitely not Other action none remedial the hospitalization	n(s) taken erapy - pharmacolerapy - nonpharma	ogic	(mm/dd/yyyy)
SAE Description Onset Date Reported to FDA by: Reported to Sponsor Reported to NIDA by Severity grade Was SAE related to in definitely Action taken regarding none discontinued per discontinued ter	mild probab probab ng investig rmanently mporarily	moderate nal agent? ly possibly ational agent reduced dose increased dose delayed dose	Date reported to	finitely not Other action none remedial the hospitalization	n(s) taken erapy - pharmacolerapy - nonpharma	ogic	(mm/dd/yyyy)
SAE Description Onset Date Reported to FDA by: Reported to Sponsor Reported to NIDA by Severity grade Was SAE related to in definitely Action taken regarding none discontinued permitted discontinued termitted	mild probab probab mg investig rmanently mporarily was death, a [moderate nal agent? ly possibly ational agent reduced dose increased dose delayed dose Death Report Case Report	Date reported to Initial Date repo severe remotely de Form must be complet	finitely not Other action none remedial the hospitalization	n(s) taken erapy - pharmacolerapy - nonpharma	ogic	(mm/dd/yyyy)

	boratory data, incl					
Dalamant biotamai						
	ncluding pre-existi hol use, hepatic/re			<u>ergies, preg</u> i	nancy,	
SAE resolution da	to	(mm/dd/	vvv) (or	uina	
	ENT ADMINISTRATI				g	
	onal agent informa		Y	es No		
If yes, investigati	onal agent name	<u> </u>	_			
Lot number						
Expiration date		(mm/dd/	уууу)			
<u>Quantity</u>						
Unit Code		Other	<u>unit</u>			
Start date	(mm/dd/yyyy)	Stop date	(mm/dd		or continu	uing
Rout	e of administration	1		Frequency		
auricular	<pre>rectal</pre>		single	dose		
inhaled	subcutane	ous	once o			
intra-articular	sublingual			other day		
intramuscular	transderma	al	twice			
intraocular	vaginal			times a day		
intravenous	unknown	oif.()		imes a day		
nasal	other (spe	city)	as nee			
oral			other	(Specify)		
Community						
<u>Comments</u>						

Protocol Number: NIDA-CPU-000	4		Site Identification Number: 980101
GBR 12909 for Cocaine Depender	псе		Subject Identification Number: 0001
Study Day UNSCHD		Form Not Done	Date: (mm/dd/yyyy)
			(11111) (117) (117)
	SAFTEI	E GI-COMBINE (Page 1)	
Complete at all visits for	r participants that are assign	ned to MM. For further instructions, see	SAFTEE guidelines in the MM manual.
PATTERN	SEVERITY	DRUG RELATED	ACTION TAKEN
IS = Isolated IN = Intermittent CO = Continuous	MN = Minimal MI = Mild MO = Moderate S = Severe	N = No DR = Dose-response TO = Timing of onset K = Known drug effect O = Other (specify) X = Don't Know	N = None IS = Increased surveillance C = Contra active RX SU = Suspend RX DC = Discontinue RX O = Other R = Dose Reduction I = Dose Increased
Line # 1 Drug Related Specify:	Mont		tern Severity Drug Action Related Taken

Protoc	ol Number: NIDA-C	PU-000)4					Site Ide	ntification	Number:	980101
GBR 12909 for Cocaine Dependence						:	Subject Ide	ntification	Number:	0001	
Study Day UNSCHD					Fo	orm Not Dor	ne 🗌		Dat		/dd/yyyy)
										(11111	, uu, yyyy,
				SAFTEE	GI-CO	MBINE (Pa	age 2)				
	Complete at a	ll visits fo	r participants	that are assigned	ed to MM.	For further inst	tructions, see S	SAFTEE guideline	es in the MM m	nanual.	
	PATTERN		SEV	ERITY		DRUG RELAT	TED	AC	TION TAKE	N	
	IS = Isolated		MN =	Minimal	N	= No		N = No	one		
	IN = Intermitte CO = Continuo			Mild	DR	= Dose-respor			creased survei		
	CO = Continuo	us		Moderate Severe	TO K	= Timing of or= Known drug			ontra active R> uspend RX	(
					0	= Other (spec			scontinue RX		
					Х	= Don't Know		O = O			
									ose Reduction ose Increased		
<u>s</u>	tudy Specific	<u>E</u>	<u>VENT</u>	Date of C		Duration	<u>Pattern</u>	Severity	<u>Drug</u>	<u>Action</u>	
1 N	<u>Events</u>			(Month)	(Day)	(Days)			Related	<u>Taken</u>	- I
1. Naus	sea					<u> </u>					_
<u> </u>		Drug Re Specify					Description*				
								ļ			<u></u>
<u>s</u>	tudy Specific	<u>E</u>	<u>VENT</u>	Date of C	<u>Onset</u>	<u>Duration</u>	<u>Pattern</u>	Severity	<u>Drug</u>	<u>Action</u>	
	<u>Events</u>			(Month)	(Day)	(Days)			Related	<u>Taken</u>	_
2. Vom	iting					<u> </u>				<u> </u>	_
<u> </u>		Drug Re Specify					Description*				
				1							_
<u>s</u>	tudy Specific	<u>E</u>	<u>VENT</u>	Date of C		<u>Duration</u>	<u>Pattern</u>	Severity	<u>Drug</u>	<u>Action</u>	
D. D.	<u>Events</u>			(Month)	(Day)	(Days)			Related	<u>Taken</u>	_
3. Diari	rnea	<u> </u>				<u> </u>				<u> </u>	_
		Drug Re Specify					Description*				
							1	<u> </u>			_
<u>s</u>	tudy Specific	<u>E</u>	<u>VENT</u>	Date of C		<u>Duration</u>	<u>Pattern</u>	<u>Severity</u>	<u>Drug</u>	<u>Action</u>	
4 4 5 -	<u>Events</u>			(Month)	(Day)	(Days)			Related	<u>Taken</u>	- I
4. Abdo	ominal Pain	<u> </u>				<u> </u>				<u> </u>	_
		Drug Re Specify					Description*				
				1							
<u>s</u>	tudy Specific	E	<u>VENT</u>	Date of C		<u>Duration</u>	<u>Pattern</u>	Severity	<u>Drug</u>	<u>Action</u>	
F 5	Events			(Month)	(Day)	(Days)			Related	<u>Taken</u>	_
5. Decr	reased Appetite					<u></u>				<u> </u>	
		Drug Re Specify					Description*				
							1				

ı

Study Specific	<u>EVENT</u>	Date of Onset	<u>Duration</u> <u>Pattern</u>	Severity	<u>Drug</u> <u>Action</u>
<u>Events</u>		(Month) (Day)	(Days)		Related Taken
6. Increased Appetite					
	Drug Related Specify:		Description*		
Study Specific Events	EVENT	Date of Onset (Month) (Day)	Duration Pattern (Days)	Severity	Drug Action Related Taken
7. Headache	Drug Related Specify:				
Study Specific Events	EVENT	Date of Onset (Month) (Day)	<u>Duration</u> <u>Pattern</u> (Days)	Severity	Drug Action Related Taken
8. Dizziness	<u> </u>				
	Drug Related Specify:		<u>Description*</u>		
Study Specific Events	EVENT	Date of Onset (Month) (Day)	<u>Duration</u> <u>Pattern</u> (<u>Days</u>)	<u>Severity</u>	Drug Action Related Taken
9. Fatigue					
	Drug Related Specify:		Description*		
Study Specific Events	EVENT	Date of Onset (Month) (Day)	<u>Duration</u> <u>Pattern</u> (<u>Days</u>)	<u>Severity</u>	Drug Action Related Taken
10. Nervousness/anxiety	<u> </u>				
	Drug Related Specify:		<u>Description*</u>		
Study Specific Events	EVENT	Date of Onset (Month) (Day)	<u>Duration</u> <u>Pattern</u> (<u>Days)</u>	Severity	Drug Action Related Taken
11. Insomnia					
	Drug Related Specify:		Description*		
Study Specific Events	EVENT	Date of Onset (Month) (Day)	<u>Duration</u> <u>Pattern</u> (<u>Days)</u>	Severity	Drug Action Related Taken
12. Somnolence					
	Drug Related Specify:		Description*		
Study Specific Events	EVENT	Date of Onset (Month) (Day)	Duration Pattern (Days)	Severity	Drug Action Related Taken
13. Depression**	<u> </u>				
	Drug Related Specify:		<u>Description*</u>		
	I			1	,

Study Specific	<u>EVENT</u>	Date of Onset	<u>Duration</u> <u>Pattern</u>	Severity	<u>Drug</u>	Action
<u>Events</u>		(Month) (Day)	(Days)		Related	<u>Taken</u>
14. Itching						
	Drug Related Specify:		Description*			
Study Specific Events	<u>EVENT</u>	Date of Onset (Month) (Day)	Duration Pattern (Days)	Severity	Drug Related	Action Taken
15. Rash	Drug Related Specify:					
Study Specific Events	<u>EVENT</u>	Date of Onset (Month) (Day)	Duration Pattern (Days)	Severity	<u>Drug</u> <u>Related</u>	Action Taken
16. Decreased Libido						
	Drug Related Specify:		Description*		.,	
Study Specific Events	EVENT	Date of Onset (Month) (Day)	Duration Pattern (Days)	Severity	Drug Related	Action Taken
17. Increased Libido	<u> </u>					
	Drug Related Specify:		<u>Description*</u>			
Study Specific Events	<u>EVENT</u>	Date of Onset (Month) (Day)	Duration Pattern (Days)	Severity	Drug Related	<u>Action</u> <u>Taken</u>
18. Missed menses						
	Drug Related Specify:		<u>Description*</u>			
Study Specific Events	<u>EVENT</u>	<u>Date of Onset</u> (Month) (Day)	Duration Pattern (Days)	Severity	Drug Related	Action Taken
19. Significant Lab Abnormalities (describe)						
	Drug Related Specify:		<u>Description*</u>			
Study Specific Events	<u>EVENT</u>	Date of Onset (Month) (Day)	Duration Pattern (Days)	Severity	Drug Related	Action Taken
20. Other (describe)						
	Drug Related Specify:		Description*			
Study Specific Events	EVENT	Date of Onset (Month) (Day)	Duration Pattern (Days)	Severity	<u>Drug</u> <u>Related</u>	Action Taken
21. Other (describe)			<u> </u>			
	Drug Related Specify:		<u>Description*</u>			

Study Specific Events 22. Other (describe)	EVENT	<u>Date of Onset</u> (Month) (Day)	Duration (Days)	<u>Pattern</u>	Severity	<u>Drug</u> <u>Related</u>	Action Taken	
	Drug Related Specify:			Description*			<u> </u>	
Study Specific Events 23. Other (describe)	EVENT Drug Related Specify:	Date of Onset (Month) (Day)	Duration (Days)	Pattern Description*	Severity	<u>Drug</u> <u>Related</u>	Action Taken	
Source Completed By (Initials): SAFTEE2 v1								E2 v1

Protocol Number: NIDA-CPU-0004	Site Identification Number:	980101
GBR-12909 for Cocaine Dependence	Subject Identification Number:	0001
Study Day UNSCHD	Date:	(mm/dd/yyyy)
	SCID WORKSHEET	
AXIS I - Diagnosis		
Please list all CURRENT and PA	AST Substance Abuse or Dependence Diagnoses,	
OTHER CURRENT, AND OT	HER PAST Diagnoses (Include DSM-IV code).	
Line Axis I DSM-	IV Diagnosis	
No. Diagnoses Type Code	9	
	<u>-</u>	
Source Completed By (Initials):		
		SCID v1

GBR-12909 for Co	caine Dependence		Subject Id	dentification Number:	0001
Study Day	UNSCHD			Date:	/ / / / / /
		Form Not Done			(mm/dd/yyyy)
		COLLECTION OF UP	RINE SPECIMENS	3	7
	FOR GBR	12909 ELIMINATI	ON PHARMACO	KINETICS	
	<u>Time</u>	Start Time	Stop Time	Total Volume	
		(00:00 - 23:59)	(00:00 - 23:59)	Collected	
	0 - 8 hours			ml	
	8 - 16 hours			ml	
	16 - 24 hours			ml	
		1			
	Source Completed By (Initials				

Protocol Number: NIDA-CPU-0004				Site I	Identification Number:	980101			
GBR-12909 for Cocaine Dependence				Subject I	Identification Number:	0001			
Study Day	UNSCI	HD		orm Not Done	Date:	(mm/dd/yyyy)			
			UR	INALYSIS					
	Indicate whether the laboratory value is NORMAL: within normal limits, ABNORMAL: outside of normal limits but not clinically significant, ABNORMAL SIGNIFICANT: significant during screening means subject is ineligible for study; significant while on study means consider reporting result as adverse event if unexpected and at least possibly related to investigational agent, or requires early termination from study.								
<u>Dipstick</u>	<u>Urinalysis:</u>								
		c gravity		Color					
	рН			Appearance					
					1				
					1				
						_			
		Source Completed	By (Initials):			URINE v1			

	r: NIDA-CPU-0004 Cocaine Dependence UNSCHD	Site Identification Number: 980101 Subject Identification Number: 0001 Date: (mm/dd/yyyy)				
		URINE TOXICOLOGY				
<u>Urine tem</u>	perature within expected range?	Yes				
	Drug/Test	Positive Negative Not Done				
	Amphetamines					
	Barbiturates					
	Benzodiazepines					
	Cannabinoids (THC)					
	Cocaine metabolites					
	Methadone					
	Methamphetamine					
	Methaqualone					
	Opiates					
	Phencyclidine (PCP)					
	Propoxyphene					

Protocol Number: NIDA-CPU-0004 GBR-12909 for Cocaine Dependence Study Day UNSCHD			Form No		te Identification Numbe ct Identification Numbe Dat	r: 0001
			VITAL SIGNS	(Days 1-11)		
Hour	Time (00:00 - 23:59)	Temp (oral) Fahrenheit or Celcius	Resp. Rate (Breaths/Min)	Pulse Rate (Beats/Min)	Blood Pressure (systolic) / (diastolic)	Comp.By: (Initials)
0		□F □C			/	
					/	
					/	
					/	
					/	
					/	
					/	
						VITALS v1

Protocol Number: NID.			Site Identification Nur	nber : 980101		
GBR-12909 for Cocain	e Dependence		Subject Identification Number			
Study Day UN			ı	Date:		
		Form	Not Done		(mm/dd/yyyy)	
Г	VIT	'AL CICNE (Cor	coning / Davis	12 47)		
	VII	AL SIGNS (SCI	eening / Days	12-47)		
Time (00:00 - 23:59)	Temp (oral) Fahrenheit or Celcius	Resp. Rate (Breaths/Min)	Pulse Rate (Beats/Min)	Blood Pressure (systolic) / (diastolic)	Comp.By: (Initials)	
	□F □C			/		
		•				
					VITALS2 v1	